Skip to main content

Therapeutics Guidelines Group


Veterinarians throughout the world rely on various nutritional, chemical (e.g., disinfectants), pharmaceutical, and biological products to allow them to effectively prevent, diagnose, and treat the various illnesses that afflict companion animals. While varying in incidence, these conditions are global in scope and benefit from a common approach to their diagnosis and management. The WSAVA has as one of its core goals developing guidelines promoting standards of care that often encompass appropriate use of nutritional, chemical, pharmaceutical, and biological products. However, there are contemporary and evolving issues common to these products that would benefit from a focus on their appropriate stewardship. Currently, the two most common issues are antimicrobial resistance and product accessibility, however there are emerging issues (e.g., compounding, black market access, etc) that would benefit from a collaborative and global approach to their understanding and guidance formulation. The primary remit of the TGG is to monitor and address these issues as they become relevant to the global companion animal community, and to provide guidance as to a collaborate approach to address these through continuing education,  minimum standards, and stakeholder engagement, based on an evidence-based medicine approach.

New WSAVA Position Statement on Equitable Access to Veterinary Therapeutics for Veterinarians Globally

“Ready access by healthcare professionals to pharmaceuticals (e.g., medicines, anesthetics/analgesics, etc), biologicals (e.g., vaccines, etc), parasiticides, and antiseptics is one of the key pillars of appropriate patient care, whether in human or veterinary medicine. Inequities in availability and access exist between various regions of the world for a variety of reasons. We call upon key stakeholders (regulatory authorities, manufacturers, and healthcare professionals) to seek solutions that would broaden access while maintaining the sanctity of the veterinary-client-patient+/- pharmacist relationship, where warranted.”

This joint position statement stems from an earlier more comprehensive WSAVA statement (in the Resources section) which was developed based on member engagement on this issue.


  • World Small Animal Veterinary Association (WSAVA)
  • World Veterinary Association (WVA)
  • Federation of Veterinarians of Europe (FVE)
  • Commonwealth Veterinary Association (CVA)
  • La Fédération des Associations Francophone de Vétérinaires (FAFVAC)
  • Federation of Asian Veterinary Associations (FAVA)
  • Federation of Asian Small Animal Veterinary Associations (FASAVA)
  • Federation of European Companion Animal Veterinary Associations (FECAVA)
  • Federacion Iberoamericana de Asociaciones Veterinarias de Animales de Compania (FIAVAC)
  • Health for Animals

Endorse the Position Statement (PDF).


We’re delighted that the following WSAVA members have already endorsed our Position Statement:

  • Belgium - SAVAB
  • Canada - AMVQ
  • Denmark - DSAVA
  • Estonia - ESAVA
  • Greece - HCAVS
  • India - FSAPAI
  • Ireland - VICAS
  • Kenya - KESCAVA
  • Malaysia - MSAVA
  • Norway - NSAVA
  • North American Veterinary Conference - NAVC
  • the Netherlands - NACAM
  • the Philippines - PAHA
  • Poland - PSAVA
  • Portugal - APMVEAC
  • Serbia - SASAP
  • Singapore - SVA
  • South Africa - SAVA
  • Swiss Society of Veterinary Dentistry - SSVD

The Therapeutics Guideline Group is being launched soon. Be sure to check back regularly for further updates and Committee Resources.